A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Summary

This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Timeline

Start

2012-10

Primary completion

2016-01

Completion

2016-01

Drugs

Indications